Pleural Fluid Transforming Growth Factor–β1 Correlates with Pleural Fibrosis in Experimental Empyema

Sasse, Scott A.; Jadus, Martin R.; Kukes, Gary

doi:10.1164/rccm.2202043

Cited by 51 publications

(37 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-TGF-␤ strategies are a promising therapeutic approach for prevention or cure these complications. One study has shown that intrapleural injection of TGF-␤ Abs can reduce empyema-induced pleural fibrosis in a rabbit model (11,12). Although the role of TGF-␤ in other pleural fibrotic disorders is not definitively proven, we believe that our model could be very useful to further understand how to halt the progression or even cure this chronic condition.…”

Section: Discussionmentioning

confidence: 93%

“…It has recently been shown that intrapleural injection of TGF-␤2 stimulates mesothelial cells to produce collagen and endogenous TGF-␤, further increasing the production of matrix proteins (10). Human mesothelial cells are not only able to synthesize TGF-␤ but also have receptors for this cytokine (11,29), further supporting the hypothesis of autocrine activation of TGF-␤ in pleural fibrosis.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

TGF-β1 Induces Progressive Pleural Scarring and Subpleural Fibrosis

Decologne

Kolb

Margetts

et al. 2007

The Journal of Immunology

118

119

View full text Add to dashboard Cite

Pleural fibrosis is a misunderstood disorder which can cause severe restrictive lung disease with high morbidity and even mortality. The condition can develop in response to a large variety of diseases and tissue injury, among them infectious disease, asbestos, drugs, and radiation therapy. There is no efficient treatment to reverse established pleural fibrosis. TGF-β1 is suspected, even if not proven, as a key cytokine in this process. In this study, we used adenoviral gene transfer of TGF-β1 to the pleural mesothelium in rats. We show that local and transient TGF-β1 overexpression induces homogenous, prolonged, and progressive pleural fibrosis without pleurodesis, associated with severe impairment of pulmonary function. We further demonstrate that pleural fibrosis can expand into the lung parenchyma from the visceral layer, but not into the muscle from the parietal layer. We provide evidence that matrix accumulation and fibrosis within the parenchyma evolved through a process involving “mesothelial-fibroblastoid transformation” and suggest that the pleural mesothelial cell may be an important player involved in the development of the subpleural distribution pattern known to be a hallmark of pulmonary fibrosis. This new model of pleural fibrosis will allow us to better understand the mechanisms of progressive fibrogenesis, and to explore novel antifibrotic therapies in the pleural cavity.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 95%

TGF-β1 Induces Progressive Pleural Scarring and Subpleural Fibrosis

Decologne

Kolb

Margetts

et al. 2007

The Journal of Immunology

118

119

View full text Add to dashboard Cite

show abstract

“…Secretion of TGF-␤ and IL-10 by DOC, MSC, DOC-IFN-␥, and MSC-IFN-␥ were tested with the medium collected from the wells of MLC plates. The assay procedure followed instructions of the BioSource Mouse IL-10 ELISA kit (BioSource International) (36) and the Quantikine TGF-␤1 Immunoassay kit (R&D Systems) (37,38). Absorbance was measured with an ELx800UV ELISA plate reader at 450 nm.…”

Section: Alloimmunogenicity Testing Of Doc In Vitromentioning

confidence: 99%

The Immunogenicity and Immunomodulatory Function of Osteogenic Cells Differentiated from Mesenchymal Stem Cells

Liu

Kemeny

Heng

et al. 2006

The Journal of Immunology

191

165

View full text Add to dashboard Cite

Multipotent mesenchymal stem cells (MSC) are reported to be immunoprivileged as well as immunosuppressive. Hence, they are ideal candidates for allogeneic transplantation to induce regeneration of diseased tissues and organs. However, it is not known whether MSC would retain their immunoprivileged and immunomodulatory properties after differentiating into the local cell types of the transplantation site. This study sought to investigate this question with a novel New Zealand White rabbit osteogenesis model. Results showed that osteogenic cells differentiated from MSC (DOC) in vitro did not express the MHC class II molecule, were incapable of inducing allogeneic lymphocyte proliferation in mixed lymphocyte culture or generating CTL, were inhibitory in ongoing lymphocyte proliferation, and secreted anti-inflammatory cytokines (IL-10 and TGF-β). There was a significantly higher secretion of IL-10 by DOC than that by MSC, while there was no significant difference between the TGF-β secretion of MSC and DOC in vitro. However, after IFN-γ treatment, TGF-β secretion by DOC significantly decreased despite the increased production by MSC. Four weeks after local DOC implantation, despite MHC class II expression, second-set allogeneic skin rejection showed similar survival to first-set allogeneic skin rejection and DOC appeared to function as osteoblasts. In conclusion, DOC retained their immunoprivileged and immunomodulatory properties in vitro, but the latter was lost following transplantation.

show abstract

“…3) The final ''organising'' stage of pleural infection is characterised by fibroblast growth and proliferation, resulting in the formation of an inelastic, fibrous pleural peel which impairs lung re-expansion. The mechanisms which underlie the development of pleural fibrosis in empyema are poorly understood, although recent work using a rabbit model of empyema has suggested an important role for the fibrogenic transforming growth factor-b1 [18].…”

Section: Pathogenesis and Rationale For Treatmentmentioning

confidence: 99%

Advanced techniques in medical thoracoscopy

Tassi¹,

Davies²,

Noppen³

2006

Eur Respir J

103

View full text Add to dashboard Cite

For expert pulmonologists, advanced procedures in medical thoracoscopy are the nonroutine and more complex applications of the method. The main current indications are the treatment of infected pleural space, forceps lung biopsy and sympathectomy.In parapneumonic effusions and empyema, medical thoracoscopy is as a drainage procedure, intermediate between tube thoracostomy and video-assisted thoracoscopic surgery (VATS), which is efficient, significantly lower in cost and avoids surgical thoracoscopy under general anaesthesia. It is essential that it is performed early in the course of the disease and is particularly advisable for frail patients at high surgical risk.The efficacy of forceps lung biopsy has been demonstrated in diffuse lung diseases, whereas results in localised lung diseases and chest-wall lesions have been less positive. However, VATS is currently the preferred approach for these indications. The technique still maintains its efficacy for visceral pleura and peripheral lung biopsy, in particular in the presence of pleural effusion and lung disorders.At the present time, thoracoscopic sympathectomy is minimally invasive and is an accepted intervention for patients with a variety of autonomous nervous system disturbances. Essential hyperhidrosis patients, and well-selected patients with other disorders, can be helped with this procedure, which can also be performed by interventional pulmonologists.

show abstract

Pleural Fluid Transforming Growth Factor–β1 Correlates with Pleural Fibrosis in Experimental Empyema

Cited by 51 publications

References 24 publications

TGF-β1 Induces Progressive Pleural Scarring and Subpleural Fibrosis

TGF-β1 Induces Progressive Pleural Scarring and Subpleural Fibrosis

The Immunogenicity and Immunomodulatory Function of Osteogenic Cells Differentiated from Mesenchymal Stem Cells

Advanced techniques in medical thoracoscopy

Contact Info

Product

Resources

About